Featured Research

from universities, journals, and other organizations

Trial Shows Circulating Tumor Cells Predict How Prostate Cancer Patients Do With Chemotherapy

Date:
June 5, 2007
Source:
Thomas Jefferson University
Summary:
The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial. The findings, if backed by larger studies, could have important implications for designing personalized treatments for this very dangerous type of prostate cancer, says a Jefferson Medical College researcher.

The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial. The findings, if backed by larger studies, could have important implications for designing personalized treatments for this very dangerous type of prostate cancer, the researchers say.

The team of scientists -- including first author Jose Moreno, M.D., clinical associate professor of urology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Kimmel Cancer Center at Jefferson -- looked at circulating tumor cells (CTCs) in 240 men with metastatic prostate cancer that failed hormone-depletion therapy. They compared levels prior to chemotherapy and after two to five weeks of treatment. They found that those men with more than five tumor cells per blood sample had a worse prognosis than those who had fewer cells. One half of the patients with more than five CTCs lived at least 10 months, whereas half of the men with fewer tumor cells lived substantially longer -- 21 months.

Dr. Moreno presents the trial's findings June 4, 2007 at the annual meeting of the American Society of Clinical Oncology in Chicago.

The results of the 65-site trial also showed that those patients who underwent chemotherapy and whose CTC number went down fared better and had a more favorable prognosis. That is, the level of response to chemotherapy was reflected in the CTC level, notes Dr. Moreno. The numbers held up even after up to 20 weeks of treatment. "If chemotherapy doesn't reduce the CTC level, it's information that enables the physician to change the drug regimen or perhaps stop treatment," he says.

Dr. Moreno notes that the prostate specific antigen has been a powerful biomarker for cancer presence and a useful way to gauge treatment effectiveness for years, though it has some flaws. He thinks that the group's findings show that CTCs can be a stronger marker.

"The other exciting aspect is in looking at men with earlier stage prostate cancer," he says. "One in four men may have circulating tumor cells at an early stage of prostate cancer. If we can identify those patients, perhaps we can observe and not treat with radical surgery because their cancer is more dormant."

Huntington Valley, Pa.-based Immunicon Corporation's technology enabled researchers to visualize circulating tumor cells by using immunomagnetic beams that bind to the cell surface. It's been Food and Drug Administration-approved for clinical use in breast cancer.

Immunicon currently is working with several pharmaceutical companies in identifying targets on circulating tumor cells that are susceptible to various chemotherapy drugs, he explains. "Then doctors can select specific chemotherapy agents for specific patients," Dr. Moreno says. "The first immediate application is personalized medicine in advanced metastatic prostate cancer."

In addition, certain tests can be performed on CTCs, he notes. One future goal is to better characterize the tumor cells virulence.

Yet, one limitation is that "we didn't find as many circulating cells as we thought we would." In the study, circulating tumor cells weren't found in 38 percent of the men. "That might mean a better prognosis, but in fact their prognosis still isn't very good," he points out. "There are some limitations in our ability to detect them."


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Trial Shows Circulating Tumor Cells Predict How Prostate Cancer Patients Do With Chemotherapy." ScienceDaily. ScienceDaily, 5 June 2007. <www.sciencedaily.com/releases/2007/06/070604124055.htm>.
Thomas Jefferson University. (2007, June 5). Trial Shows Circulating Tumor Cells Predict How Prostate Cancer Patients Do With Chemotherapy. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2007/06/070604124055.htm
Thomas Jefferson University. "Trial Shows Circulating Tumor Cells Predict How Prostate Cancer Patients Do With Chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2007/06/070604124055.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
'Cadaver Dog' Sniffs out Human Remains

'Cadaver Dog' Sniffs out Human Remains

AP (Oct. 21, 2014) Where's a body buried? Buster's nose can often tell you. He's a cadaver dog, specially trained to find human remains and increasingly being used by law enforcement and accepted in courts. These dogs are helping solve even decades-old mysteries. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins